F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With Acute Myeloid Leucemia(AML)

F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With AML

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01592266

Acronym

AML F18-FLT

Enrollment

Registered

2012-05-07

Start date

2012-10-31

Completion date

Unknown

Last updated

2012-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leucemia

Keywords

FLT, PET, bone marrow, AML

Brief summary

PET/CT is reliable tool in evaluation of treatment response in number cancers. F18-FLT is a precursor of DNA with high uptake in the bone marrow as a part of normal biodistribution. Highly increased uptake of this radiopharmaceutical was shown in a number of hematologic disease either in bone marrow or extramedullary. F18-FLT PET/CT can provide a tool for whole body assessment of activity in bone marrow as well as early estimation of treatment efficacy or lack of it. In addition, this noninvasive study can replace bone marrow biopsy and predict response vs. non response to therapy.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* new diagnosis of AML

Exclusion criteria

* pregnancy

Design outcomes

Primary

Measure	Time frame
Measure of extent and intensity ( by standardized uptake value - SUV) of disease in bone marrow demonstrated on PET/CT images before and after treatment.	—

Secondary

Measure	Time frame
prediction of treatment response by dynamics of FLT uptake(by SUV)in comparison to bone marrow biopsy	—

Countries

Israel

Contacts

Primary ContactMarina Orevi, MD

marinaor@hadassah.org.il

Outcome results